April 24, 2002
AmeriPath to Report Financial Results for First Quarter Ended March 31, 2002

- Tuesday, April 30, 2002, Before Market -

Riviera Beach, FL, April 24, 2002 – AmeriPath, Inc. (Nasdaq:PATH), one of the nation’s leading providers of anatomic pathology services, today announced that it plans to release its complete financial results for the first quarter ended March 31, 2002 on Tuesday, April 30, 2002, before the market opens.

The Company will broadcast its full financial results conference call on Tuesday, April 30, 2002, at 10:00 a.m. Eastern Time over the Internet. The call will by hosted by James C. New, Chairman and Chief Executive Officer, and Gregory A. Marsh, Vice President and Chief Financial Officer. All stockholders and investors are encouraged to participate. This event is available by visiting the Company’s website located at http://www.ameripath.com, or through CCBN’s website, located at http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=PATH&script=1020&item_id=ew,621485,1&layout=6. Listeners should go to one of these websites at least fifteen minutes before the call to register and to download and install any necessary audio software. For those unable to attend the live webcast, a replay will be available on these websites for the next 60 days. There is no charge to access the event. A replay of the call will also be available by telephone beginning at 12:00 p.m., April 30th to 12:00 p.m., May 2nd. The dial-in number for the telephone replay is 800-633-8284, ID #20526351.

AmeriPath is a leading national provider of cancer diagnostics, genomics, and related information services. During 2001, AmeriPath diagnosed approximately 4.0 million tissue biopsies, and interpreted approximately 2.1 million Pap smears. The company’s extensive diagnostics infrastructure includes over 400 pathologists and doctorate-level scientists providing services in over 40 independent pathology laboratories, more than 200 hospitals, the Center for Advanced Diagnostics (CAD) and Dermpath Diagnostics, a division of AmeriPath. CAD provides specialized diagnostic testing and information services including Fluorescence In-Situ Hybridization (FISH), Flow Cytometry, DNA Analysis, Polymerase Chain Reaction (PCR), Molecular Genetics, Cytogenetics and HPV Typing. AmeriPath has over 60 board-certified dermatopathologists supporting Dermpath Diagnostics, one of the country’s leading providers of dermatopathology services in the growing skin diagnostic market. Additionally, AmeriPath provides clinical trial and research development support to firms involved in developing new cancer and genomic diagnostics and therapeutics.